A lot of times when companies have secondary offerings the price takes a slight dip to accommodate the dilution and price. However a landslide drop of almost 15% is not often in…
Chris Lange ThinkstockInvestors love to see insiders at high corporate levels purchasing their own companies’ stock. That is particularly true if the stock has performed well and has traded to higher levels. With the…
ThinkstockWith the top stocks in the market exploding in price due to the recent rally, we wanted to scan across our research universe for some lower priced names that could have significant…
August 5, 2013: U.S. equity markets opened lower this morning, lacking any major news of interest from around the globe. In Europe, eurozone non-manufacturing PMI rose slightly even though German PMI was…
Today was a crazy day for the markets, and as you’d expect there were many movers in the drug and biotech sectors. Today’s edition of the BioHealth Business Daily covers ARCA biopharma,…
As first reported at our affiliate site BioHealth Investor: Inovio Biomedical Corporation (NYSE Amex: INO) has been higher by over 160% for most of the morning. Investors are following the news reports this…
Douglas A. McIntyre (ALTH) Allos Therapeutics trading down 20% after its Phase III study of Efaproxyn failed to meet primary endpoint of improvement in overall survival.(BAY) Bayer raised guidance on Schering integration.(BMY) Bristol-Myers: FDA Grants…
